0001477932-22-004666.txt : 20220624
0001477932-22-004666.hdr.sgml : 20220624
20220624160552
ACCESSION NUMBER: 0001477932-22-004666
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220623
FILED AS OF DATE: 20220624
DATE AS OF CHANGE: 20220624
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brudnick Richard
CENTRAL INDEX KEY: 0001692359
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36833
FILM NUMBER: 221040064
MAIL ADDRESS:
STREET 1: BIOVERATIV INC.
STREET 2: 225 SECOND AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VOLITIONRX LTD
CENTRAL INDEX KEY: 0000093314
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 911949078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 13215 BEE CAVE PARKWAY,
STREET 2: SUITE 125, GALLERIA OAKS B
CITY: AUSTIN
STATE: TX
ZIP: 78738
BUSINESS PHONE: 1 (646) 650-1351
MAIL ADDRESS:
STREET 1: 13215 BEE CAVE PARKWAY,
STREET 2: SUITE 125, GALLERIA OAKS B
CITY: AUSTIN
STATE: TX
ZIP: 78738
FORMER COMPANY:
FORMER CONFORMED NAME: STANDARD CAPITAL CORP
DATE OF NAME CHANGE: 19990812
4
1
form4.xml
FORM 4
X0306
4
2022-06-23-05:00
false
0000093314
VOLITIONRX LTD
VNRX
0001692359
Brudnick Richard
13215 BEE CAVE PARKWAY, SUITE 125
GALLERIA OAKS B
AUSTIN
TX
78738
true
false
false
false
Common Stock
2022-06-23-05:00
4
A
false
3046
0
A
19686
D
Stock Option (Right to Buy)
3.40
2022-06-23-05:00
4
A
false
5613
0
A
2031-08-03-05:00
Common Stock
5613
8635
D
On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,046 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,523 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 1,640 restricted stock units subject to the award previously vested and remain subject to time-based vesting.
On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting.
/s/ Richard Brudnick
2022-06-24-05:00